File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer

TitleOne-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer
Authors
Issue Date1998
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
Citation
Alimentary Pharmacology And Therapeutics, 1998, v. 12 n. 8, p. 725-730 How to Cite?
AbstractBackground: Proton pump inhibitors have been widely used in combination with amoxycillin, clarithromycin or metronidazole for the treatment of Helicobacter pylori infection. Aim: To study the effects of 1-week ranitidine bismuth citrate (RBC)-based triple therapy in the treatment of H. pylori-related duodenal ulcers. Method: Patients with duodenal ulcers and II. pylori infection were prospectively randomized to receive either RBC with amoxycillin and clarithromycin for 1 week (RAC), or omeprazole with amoxycillin and clarithromycin for 1 week (OAC). No additional ulcer healing drug was used after the 1-week medication. Patients were assessed for H. pylori eradication, ulcer healing and side-effects after receiving the therapies. Results: One hundred consecutive patients were recruited to this study, with 50 patients randomized to each treatment group. In the intention-to-treat analysis, duodenal ulcers were completely healed in 45 (90%) patients in the RAC group and 43 (89.6%) in the OAC group (P = 1.0). H. pylori eradication was confirmed in 47 (94%) in the RAC group and 42 (87.5%) in the OAC group (P = O.31). There was no significant difference in the severity of side-effects experienced by the two treatment groups. Conclusion: One-week RBC-based triple therapy is an effective treatment for H. pylori-related duodenal ulcers. The therapeutic effects are comparable to a 1-week course of proton pump inhibitor-based triple therapy.
Persistent Identifierhttp://hdl.handle.net/10722/162234
ISSN
2015 Impact Factor: 6.32
2015 SCImago Journal Rankings: 2.833
References

 

DC FieldValueLanguage
dc.contributor.authorSung, JJYen_US
dc.contributor.authorLeung, WKen_US
dc.contributor.authorLing, TKWen_US
dc.contributor.authorYung, MYen_US
dc.contributor.authorChan, FKLen_US
dc.contributor.authorLee, YTen_US
dc.contributor.authorCheng, AFBen_US
dc.contributor.authorChung, SCSen_US
dc.date.accessioned2012-09-05T05:18:18Z-
dc.date.available2012-09-05T05:18:18Z-
dc.date.issued1998en_US
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 1998, v. 12 n. 8, p. 725-730en_US
dc.identifier.issn0269-2813en_US
dc.identifier.urihttp://hdl.handle.net/10722/162234-
dc.description.abstractBackground: Proton pump inhibitors have been widely used in combination with amoxycillin, clarithromycin or metronidazole for the treatment of Helicobacter pylori infection. Aim: To study the effects of 1-week ranitidine bismuth citrate (RBC)-based triple therapy in the treatment of H. pylori-related duodenal ulcers. Method: Patients with duodenal ulcers and II. pylori infection were prospectively randomized to receive either RBC with amoxycillin and clarithromycin for 1 week (RAC), or omeprazole with amoxycillin and clarithromycin for 1 week (OAC). No additional ulcer healing drug was used after the 1-week medication. Patients were assessed for H. pylori eradication, ulcer healing and side-effects after receiving the therapies. Results: One hundred consecutive patients were recruited to this study, with 50 patients randomized to each treatment group. In the intention-to-treat analysis, duodenal ulcers were completely healed in 45 (90%) patients in the RAC group and 43 (89.6%) in the OAC group (P = 1.0). H. pylori eradication was confirmed in 47 (94%) in the RAC group and 42 (87.5%) in the OAC group (P = O.31). There was no significant difference in the severity of side-effects experienced by the two treatment groups. Conclusion: One-week RBC-based triple therapy is an effective treatment for H. pylori-related duodenal ulcers. The therapeutic effects are comparable to a 1-week course of proton pump inhibitor-based triple therapy.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APTen_US
dc.relation.ispartofAlimentary Pharmacology and Therapeuticsen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAmoxicillin - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshAnti-Bacterial Agents - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshAnti-Ulcer Agents - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshBismuth - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshClarithromycin - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshCombined Modality Therapyen_US
dc.subject.meshDuodenal Ulcer - Drug Therapy - Microbiologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHelicobacter Infections - Drug Therapyen_US
dc.subject.meshHelicobacter Pylori - Drug Effectsen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOmeprazole - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshPenicillins - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshProton Pumps - Pharmacologyen_US
dc.subject.meshRanitidine - Administration & Dosage - Analogs & Derivatives - Therapeutic Useen_US
dc.subject.meshSingle-Blind Methoden_US
dc.subject.meshTreatment Outcomeen_US
dc.titleOne-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulceren_US
dc.typeArticleen_US
dc.identifier.emailLeung, WK:waikleung@hku.hken_US
dc.identifier.authorityLeung, WK=rp01479en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1046/j.1365-2036.1998.00367.xen_US
dc.identifier.pmid9726384-
dc.identifier.scopuseid_2-s2.0-0031825370en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0031825370&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume12en_US
dc.identifier.issue8en_US
dc.identifier.spage725en_US
dc.identifier.epage730en_US
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridSung, JJY=35405352400en_US
dc.identifier.scopusauthoridLeung, WK=7201504523en_US
dc.identifier.scopusauthoridLing, TKW=13310253900en_US
dc.identifier.scopusauthoridYung, MY=36660279600en_US
dc.identifier.scopusauthoridChan, FKL=7202586434en_US
dc.identifier.scopusauthoridLee, YT=35477936800en_US
dc.identifier.scopusauthoridCheng, AFB=7402075035en_US
dc.identifier.scopusauthoridChung, SCS=19642462800en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats